This presentation provides translational proof-of-concept for agenT-797 in infectious/immune collapse contexts beyond oncology but lacks quantitative efficacy data. Watch for enrollment updates or early readout from the ongoing Phase 2 in severe acute lung injury. Catalytic value remains tied to Phase 2 data generation, not this single-case report.
INKT drugs
INKT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 20 $10.72entry
- T+1 · 6mo ago +2.05%α +1.86% · $10.94
- T+5 · 6mo ago −5.04%α −6.27% · $10.18
- T+20 · 5mo ago +13.25%α +12.51% · $12.14
- T+60 · 3mo ago +5.13%α +0.13% · $11.27
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MiNK Therapeutics presented a single-case report at ATS 2026 showing that sequential immunotherapy with Anktiva (N-803) and its iNKT cell therapy agenT-797 suppressed fungal/bacterial pathogens, activated immune cell recruitment, reduced inflammatory signaling, and triggered tissue repair pathways in a critically ill patient with disseminated valley fever, ARDS, and hospital-acquired pneumonia after standard-of-care failed. The data support an ongoing Phase 2 trial in severe acute lung injury, but limited to a single case without quantitative efficacy or survival endpoints.
Key Facts
- Case report: sequential Anktiva (N-803) + agenT-797 in critically ill patient with disseminated Coccidioides immitis, ARDS, and Pseudomonas pneumonia
- Observed: pathogen suppression, immune cell recruitment into lung, reduced early inflammatory signaling, activation of tissue repair pathways
- AgenT-797 already has prior safety data in moderate-severe ARDS (favorable safety, improved survival, decreased secondary infections per prior disclosure)
- MiNK recently initiated a randomized Phase 2 trial of agenT-797 in severe acute lung injury / critical illness
- Clinical data is a single case (N=1), no quantitative efficacy or survival endpoint was achieved (patient died from pre-existing mitral valve disease with cardiogenic shock)
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage biotech with $52M market cap
Risk Factors
- Patient died from pre-existing cardiac disease, confounds interpretation of immune response data
- Single case without comparator, limited statistical reliability
- Pre-revenue company with high cash burn; financing risk remains elevated
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298712 |
Track record
21 reports on INKT
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Viewing Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers